Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT04966247

Cerebral Protection in Aortic Arch Surgery

Cerebral Protection in Aortic Arch Surgery — Recruiting • Cardiology / Cardiovascular • NCT04966247.

📅 08 Sep 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT04966247
Sponsor
Barts & The London NHS Trust
Start
2023-07-19
ClinicaliQ Trial Snapshot
  • Cerebral Protection in Aortic Arch Surgery — Recruiting • Cardiology / Cardiovascular • NCT04966247.
  • Sponsor: Barts & The London NHS Trust.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Aortic arch repair surgery is a technically complex and challenging procedure to treat aortic pathologies. Despite advancements in perioperative care, detrimental neurological complications occur during or after surgery. The neurological complications increase the economic burden of healthcare, morbidity and quality of life for the patients, even if they survive. Stroke, for example, leads to an increase in healthcare and social care costs, requiring a subsequent lengthy rehabilitation. Milder neurological impairments include transient ischaemic attacks, confusion and delirium, necessitating longer intensive care and hospital stay. Currently applied cerebral monitoring modalities are…

Eligibility Snapshot
  • : * Patients undergoing aortic arch surgery * Patients aged 18 and over * Patients who are able to provide informed consent

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Aortic Valve Disease: TAVI and Surgical Replacement (NICE TA631)
Cardiology / Cardiovascular · 27 Mar 2026
Offer TAVI as first-line intervention for symptomatic aortic stenosis in patients at high or prohibitive surgical risk, or with severe comorbidities precluding…
View guideline →
Clinical Brief
3D heart to let surgeons practise baby’s vital heart operation
Cardiology / Cardiovascular · BBC Health · 07 Apr 2026
3D heart models enable surgeons to practise complex congenital heart operations preoperatively, potentially improving surgical outcomes in neonatal cases Personalised anatomical models…
View brief →
Clinical Brief
Campaigners hold vigil as stroke unit closes
Cardiology / Cardiovascular · BBC Health · 10 Sep 2026
Stroke unit closure will redirect acute stroke patients to neighbouring hospitals in Taunton or Dorchester, potentially impacting treatment times and transfer protocols…
View brief →
Clinical Brief
Man completes half marathon after two heart attacks
Cardiology / Cardiovascular · BBC Health · 26 Aug 2026
Key Takeaways for Clinical Practice Cardiac rehabilitation and secondary prevention can enable significant functional recovery post-myocardial infarction, with patients potentially returning to…
View brief →
Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Guideline
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Cardiology / Cardiovascular · 30 Jul 2026
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers,…
View guideline →